Literature DB >> 23150150

Personalizing antiplatelet therapy-moving to clinics.

Subraja Kumaresan, Steven Dkhar.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23150150     DOI： 10.1007/s00228-012-1445-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  3 in total

1.  Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.

Authors:  Emily S Reese; C Daniel Mullins; Amber L Beitelshees; Eberechukwu Onukwugha
Journal:  Pharmacotherapy       Date:  2012-04       Impact factor: 4.705

2.  Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.

Authors:  Jason D Roberts; George A Wells; Michel R Le May; Marino Labinaz; Chris Glover; Michael Froeschl; Alexander Dick; Jean-Francois Marquis; Edward O'Brien; Sandro Goncalves; Irena Druce; Alexandre Stewart; Michael H Gollob; Derek Y F So
Journal:  Lancet       Date:  2012-03-29       Impact factor: 79.321

3.  Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project.

Authors:  J M Pulley; J C Denny; J F Peterson; G R Bernard; C L Vnencak-Jones; A H Ramirez; J T Delaney; E Bowton; K Brothers; K Johnson; D C Crawford; J Schildcrout; D R Masys; H H Dilks; R A Wilke; E W Clayton; E Shultz; M Laposata; J McPherson; J N Jirjis; D M Roden
Journal:  Clin Pharmacol Ther       Date:  2012-05-16       Impact factor: 6.875
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.